Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 20, 2019
May 15, 2020
c20377b8-3086-48cf-be2b-b9cd12520573
Related Documents
Psychedelic Drugs: Considerations for Clinical Investigations
Guidance DocumentJune 23, 2023Center for Drug Evaluation and Research
Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry
Guidance DocumentJune 7, 2019Center for Drug Evaluation and Research
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry
Guidance DocumentAugust 13, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.